Abstract
Biotin protein ligase (BPL) represents a promising target for the discovery of new antibacterial chemotherapeutics. Here we review the central role of BPL for the survival and virulence of clinically important Staphylococcus aureus in support of this claim. X-ray crystallography structures of BPLs in complex with ligands and small molecule inhibitors provide new insights into the mechanism of protein biotinylation, and a template for structure guided approaches to the design of inhibitors for antibacterial discovery. Most BPLs employ an ordered ligand binding mechanism for the synthesis of the reaction intermediate biotinyl-5´-AMP from substrates biotin and ATP. Recent studies reporting chemical analogs of biotin and biotinyl-5´-AMP as BPL inhibitors that represent new classes of anti-S. aureus agents are reviewed. We highlight strategies to selectively inhibit bacterial BPL over the mammalian equivalent using a 1,2,3-triazole isostere to replace the labile phosphoanhydride naturally present in biotinyl-5´-AMP. A novel in situ approach to improve the detection of triazole-based inhibitors is also presented that could potentially be widely applied to other protein targets.
Keywords: Antibiotic, biotin, biotin protein ligase, Staphylococcus aureus, structure guided drug design, inhibitor design, Xray crystallography.
Current Topics in Medicinal Chemistry
Title:Structure Guided Design of Biotin Protein Ligase Inhibitors for Antibiotic Discovery
Volume: 14 Issue: 1
Author(s): Ashleigh S. Paparella, Tatiana P. Soares da Costa, Min Y. Yap, William Tieu, Matthew C. J. Wilce, Grant W. Booker, Andrew D. Abell and Steven W. Polyak
Affiliation:
Keywords: Antibiotic, biotin, biotin protein ligase, Staphylococcus aureus, structure guided drug design, inhibitor design, Xray crystallography.
Abstract: Biotin protein ligase (BPL) represents a promising target for the discovery of new antibacterial chemotherapeutics. Here we review the central role of BPL for the survival and virulence of clinically important Staphylococcus aureus in support of this claim. X-ray crystallography structures of BPLs in complex with ligands and small molecule inhibitors provide new insights into the mechanism of protein biotinylation, and a template for structure guided approaches to the design of inhibitors for antibacterial discovery. Most BPLs employ an ordered ligand binding mechanism for the synthesis of the reaction intermediate biotinyl-5´-AMP from substrates biotin and ATP. Recent studies reporting chemical analogs of biotin and biotinyl-5´-AMP as BPL inhibitors that represent new classes of anti-S. aureus agents are reviewed. We highlight strategies to selectively inhibit bacterial BPL over the mammalian equivalent using a 1,2,3-triazole isostere to replace the labile phosphoanhydride naturally present in biotinyl-5´-AMP. A novel in situ approach to improve the detection of triazole-based inhibitors is also presented that could potentially be widely applied to other protein targets.
Export Options
About this article
Cite this article as:
Paparella S. Ashleigh, Soares da Costa P. Tatiana, Yap Y. Min, Tieu William, Wilce C. J. Matthew, Booker W. Grant, Abell D. Andrew and Polyak W. Steven, Structure Guided Design of Biotin Protein Ligase Inhibitors for Antibiotic Discovery, Current Topics in Medicinal Chemistry 2014; 14 (1) . https://dx.doi.org/10.2174/1568026613666131111103149
DOI https://dx.doi.org/10.2174/1568026613666131111103149 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
P2Y Receptors: Focus on Structural, Pharmacological and Functional Aspects in the Brain
Current Medicinal Chemistry Activated Protein C and Acute Kidney Injury: Selective Targeting of PAR-1
Current Drug Targets Is there a Rational Approach for Increasing Drug Specificity? Considerations on CNS Target Choice and Validation
Recent Patents on CNS Drug Discovery (Discontinued) CNS Immune Surveillance and Neuroinflammation: Endocannabinoids Keep Control
Current Pharmaceutical Design Aquaporin and Vascular Diseases
Current Neuropharmacology IgG4 Related Syndrome: Another Multiorgan Disease in the Interest Field of Internal Medicine
Current Pharmaceutical Design Infectious Causes of Childhood Disability
Infectious Disorders - Drug Targets Clinical Significance of Cytokines and Chemokines in Neuropsychiatric Systemic Lupus Erythematosus
Current Rheumatology Reviews Feline Immunodeficiency Virus Model for Designing HIV/AIDS Vaccines
Current HIV Research Drug Targeting to the Brain - A Review
Current Nanoscience PDZ Domain-mediated Protein Interactions: Therapeutic Targets in Neurological Disorders
Current Medicinal Chemistry Lung Cancer Chemotherapy, New Treatment and Related Patents
Recent Patents on Anti-Cancer Drug Discovery Targeted Drug Delivery Using Tuftsin-bearing Liposomes: Implications in the Treatment of Infectious Diseases and Tumors
Current Drug Targets Transferrin Coupled Liposomes for Enhanced Brain Delivery of Doxorubicin
Vascular Disease Prevention (Discontinued) Anti-Viral Agents in Neurodegenerative Disorders: New Paradigm for Targeting Alzheimer’s Disease
Recent Patents on Anti-Infective Drug Discovery The Use of Proteomics to Study Infectious Diseases
Infectious Disorders - Drug Targets Recombinant Secretory Immunoglobulin A in Passive Immunotherapy: Linking Immunology and Biotechnology
Current Pharmaceutical Biotechnology The Role of Immune System in Schizophrenia
Current Immunology Reviews (Discontinued) Tracking Stem Cells for Cellular Therapy in Stroke
Current Pharmaceutical Design Follow-Up Study of Olfactory Deficits, Cognitive Functions, and Volume Loss of Medial Temporal Lobe Structures in Patients with Mild Cognitive Impairment
Current Alzheimer Research